GleamWall
中文EN

PTPI Petros Pharmaceuticals, Inc.

Pharmaceutical Preparations · OTC · SEC CIK 1815903 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY-12.2%
TTM net income YoY-75.4%
TTM EPS YoY-1,214.5%
Revenue 3-yr CAGR-13.2%
Net income 3-yr CAGR—

Margins

Gross margin76.3%
Operating margin-90.5%
Net margin-280.1%
FCF margin—
EBITDA margin-35.1%

Returns

ROE-622.1%
ROA-64.5%
ROIC (approx.)—
Asset turnover0.23x

Leverage & solvency

Liabilities / assets170.2%
Debt / equity—
Current ratio0.40x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.18x
Accruals ratio-52.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue—$5.11M
Cost of revenue—$1.21M
Gross profit—$3.90M
R&D expense—$2.62M
SG&A expense$4.64M$4.63M
Operating income-$4.64M-$4.63M
Interest expense—$560,909
Pretax income-$4.50M-$705,174
Income tax$0$0
Net income$1.91M-$14.32M
EBITDA—-$1.80M
EPS (basic)-1.56-83.47
EPS (diluted)-1.56-83.47
Weighted avg. shares (diluted)28.07M321,042
Banking
Net interest income$256,933$371,769
Balance sheet
Cash & equivalents$5.14M$1.72M
Receivables—$416,076
Inventory—$1.35M
Current assets$5.16M$7.29M
PP&E, net—$22,948
Intangibles—$3.20M
Total assets$5.16M$10.64M
Current liabilities$2.29M$18.03M
Total liabilities$2.29M$18.10M
Shareholders' equity$2.87M-$7.47M
Shares outstanding42.28M421,124
Cash flow statement
Operating cash flow-$6.73M-$2.60M
Capital expenditure—$24,587
Free cash flow—-$2.63M
Investing cash flow—-$24,587
Financing cash flow$8.16M-$7.00M
Depreciation & amortization—$2.83M
Stock-based compensation$304,634$197,215

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.